Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).

Fabrice André(Inserm), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Sherene Loi(The University of Melbourne), Carey K. Anders(Duke University), Tinghui Yu(AstraZeneca (Finland)), Erika Hamilton(Sarah Cannon), Pia Herbolsheimer(AstraZeneca (Finland)), Celina M. D’Cruz(AstraZeneca (United States)), Peter Schmid(St Bartholomew's Hospital), Sarice Boston(AstraZeneca (Finland))
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.tps1096
Cited by 15

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k